Courier Capital LLC Has $535,000 Stake in Zoetis Inc. (NYSE:ZTS)

Courier Capital LLC lifted its position in shares of Zoetis Inc. (NYSE:ZTS) by 80.7% during the 3rd quarter, HoldingsChannel.com reports. The firm owned 2,740 shares of the company’s stock after buying an additional 1,224 shares during the quarter. Courier Capital LLC’s holdings in Zoetis were worth $535,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in ZTS. Vanguard Group Inc. lifted its holdings in Zoetis by 1.0% during the 1st quarter. Vanguard Group Inc. now owns 40,749,571 shares of the company’s stock worth $6,895,235,000 after buying an additional 414,605 shares during the period. Bank of New York Mellon Corp grew its stake in Zoetis by 4.0% during the second quarter. Bank of New York Mellon Corp now owns 4,687,902 shares of the company’s stock worth $812,695,000 after purchasing an additional 178,303 shares during the period. Capital Research Global Investors increased its holdings in Zoetis by 2.3% in the first quarter. Capital Research Global Investors now owns 4,050,681 shares of the company’s stock worth $685,416,000 after purchasing an additional 90,330 shares in the last quarter. Clearbridge Investments LLC lifted its stake in Zoetis by 5.8% in the second quarter. Clearbridge Investments LLC now owns 3,044,384 shares of the company’s stock valued at $527,774,000 after buying an additional 166,517 shares during the period. Finally, Sarasin & Partners LLP boosted its holdings in shares of Zoetis by 546.3% during the 2nd quarter. Sarasin & Partners LLP now owns 2,253,590 shares of the company’s stock worth $390,682,000 after buying an additional 1,904,899 shares in the last quarter. 92.80% of the stock is owned by institutional investors.

Zoetis Trading Down 4.0 %

NYSE ZTS opened at $181.52 on Friday. The company has a current ratio of 3.45, a quick ratio of 2.09 and a debt-to-equity ratio of 1.32. The business has a fifty day simple moving average of $189.23 and a 200 day simple moving average of $177.58. Zoetis Inc. has a 12 month low of $144.80 and a 12 month high of $201.92. The firm has a market capitalization of $82.24 billion, a P/E ratio of 35.52, a PEG ratio of 2.94 and a beta of 0.89.

Zoetis (NYSE:ZTS) last released its quarterly earnings results on Tuesday, August 6th. The company reported $1.56 earnings per share for the quarter, topping the consensus estimate of $1.49 by $0.07. The business had revenue of $2.36 billion for the quarter, compared to analysts’ expectations of $2.31 billion. Zoetis had a net margin of 26.29% and a return on equity of 50.67%. The firm’s revenue for the quarter was up 8.3% compared to the same quarter last year. During the same period in the previous year, the company earned $1.41 earnings per share. On average, analysts predict that Zoetis Inc. will post 5.83 EPS for the current fiscal year.

Zoetis Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 3rd. Investors of record on Thursday, October 31st will be given a dividend of $0.432 per share. This represents a $1.73 dividend on an annualized basis and a dividend yield of 0.95%. The ex-dividend date is Thursday, October 31st. Zoetis’s payout ratio is 33.86%.

Analyst Ratings Changes

Several analysts have recently weighed in on the stock. Piper Sandler lifted their price objective on shares of Zoetis from $195.00 to $210.00 and gave the company an “overweight” rating in a research note on Wednesday, August 14th. Argus upgraded shares of Zoetis to a “strong-buy” rating in a report on Friday, August 9th. BTIG Research boosted their target price on Zoetis from $220.00 to $225.00 and gave the company a “buy” rating in a research report on Monday, August 12th. JPMorgan Chase & Co. increased their price target on Zoetis from $225.00 to $230.00 and gave the stock an “overweight” rating in a report on Friday, October 11th. Finally, Stifel Nicolaus boosted their price objective on Zoetis from $200.00 to $210.00 and gave the company a “buy” rating in a report on Wednesday, September 18th. Ten research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Buy” and an average price target of $221.44.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.